Session » ACR Late-breaking Abstracts Session

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: L1

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing

Abstract Number: L2

A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study

Abstract Number: L3

Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome

Abstract Number: L4

Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Abstract Number: L5

Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE)

Abstract Number: L6

A PHASE 2, Randomized, Double-Blind Comparison of the Efficacy and Safety of PF-04171327 (1, 5, 10, 15 mg QD) Vs 5 and 10 Mg Prednisone QD or Placebo in Subjects with Rheumatoid Arthritis (RA) over 8 Weeks Followed By a 4-Week Taper of Study Drug

« View all sessions from this meeting